Tumor size is strongest variable in patient response to promising melanoma drug

the ONA take:

The size of the tumor has been found to be the strongest variable in determining patients’ response to an experimental immunotherapy, MK-3475, for metastatic melanoma. The disease is generally staged as stage IVa to stage IVc based on where the cancer has spread, with the former having the best prognosis and the latter having the worse prognosis. MK-3475 is a monoclonal antibody that stimulates an immune system response to the tumor; however, larger tumors may overwhelm the effects of the drug regardless of the location of the tumor. The researchers report that this may influence treatment strategy, indicating that reducing the size of larger tumors first could lead to better outcomes for patients. MK-3475 is also being investigated in lung, bladder, and kidney cancer. The drug is on the FDA priority review list.

Tumor size is strongest variable in patient response to promising melanoma drug
Tumor size is strongest variable in patient response to promising melanoma drug
CHICAGO — In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers at Mayo Clinic in Florida found that the size of tumors before treatment was the strongest variable. Our findings suggest the location of spread is less important than the amount of tumor that is present before treatment," says the study's lead investigator, Richard W.
READ FULL ARTICLE From Science Codex
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs